Rifaximin (English Wikipedia)

Lawrence KR, Klee JA (August 2008). "Rifaximin for the treatment of hepatic encephalopathy". Pharmacotherapy. 28 (8): 1019–1032. doi:10.1592/phco.28.8.1019. PMID 18657018. S2CID 25662917. Free full text with registration at Medscape.

nih.gov (Global: 4^th place; English: 4^th place)

pubmed.ncbi.nlm.nih.gov

Koo HL, DuPont HL (January 2010). "Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases". Current Opinion in Gastroenterology. 26 (1): 17–25. doi:10.1097/MOG.0b013e328333dc8d. PMC 4737517. PMID 19881343.
DuPont HL (July 2007). "Therapy for and prevention of traveler's diarrhea". Clinical Infectious Diseases. 45 (Suppl 1): S78 – S84. doi:10.1086/518155. PMID 17582576.
Kane JS, Ford AC (2016). "Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome". Expert Review of Gastroenterology & Hepatology. 10 (4): 431–442. doi:10.1586/17474124.2016.1140571. PMID 26753693. S2CID 13607138.
Ponziani FR, Pecere S, Lopetuso L, Scaldaferri F, Cammarota G, Gasbarrini A (July 2016). "Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation". Expert Opinion on Drug Safety. 15 (7): 983–991. doi:10.1080/14740338.2016.1186639. PMID 27149541. S2CID 25426888.
Song KH, Jung HK, Kim HJ, Koo HS, Kwon YH, Shin HD, et al. (April 2018). "Clinical Practice Guidelines for Irritable Bowel Syndrome in Korea, 2017 Revised Edition". Journal of Neurogastroenterology and Motility. 24 (2): 197–215. doi:10.5056/jnm17145. PMC 5885719. PMID 29605976.
Iorio N, Malik Z, Schey R (2015). "Profile of rifaximin and its potential in the treatment of irritable bowel syndrome". Clinical and Experimental Gastroenterology. 8: 159–167. doi:10.2147/CEG.S67231. PMC 4467648. PMID 26089696.
Johnson S, Schriever C, Galang M, Kelly CP, Gerding DN (March 2007). "Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin". Clinical Infectious Diseases. 44 (6): 846–848. doi:10.1086/511870. PMID 17304459.
Garey KW, Ghantoji SS, Shah DN, Habib M, Arora V, Jiang ZD, et al. (December 2011). "A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection". The Journal of Antimicrobial Chemotherapy. 66 (12): 2850–2855. doi:10.1093/jac/dkr377. PMID 21948965.
Nelson RL, Suda KJ, Evans CT (March 2017). "Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults". The Cochrane Database of Systematic Reviews. 2017 (3) CD004610. doi:10.1002/14651858.CD004610.pub5. PMC 6464548. PMID 28257555.
Huang JS, Jiang ZD, Garey KW, Lasco T, Dupont HL (June 2013). "Use of rifamycin drugs and development of infection by rifamycin-resistant strains of Clostridium difficile". Antimicrobial Agents and Chemotherapy. 57 (6): 2690–2693. doi:10.1128/AAC.00548-13. PMC 3716149. PMID 23545528.
Lawrence KR, Klee JA (August 2008). "Rifaximin for the treatment of hepatic encephalopathy". Pharmacotherapy. 28 (8): 1019–1032. doi:10.1592/phco.28.8.1019. PMID 18657018. S2CID 25662917. Free full text with registration at Medscape.
Kimer N, Krag A, Gluud LL (March 2014). "Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy". Patient Preference and Adherence. 8: 331–338. doi:10.2147/PPA.S41565. PMC 3964161. PMID 24672227.
Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, et al. (August 2014). "Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver". Hepatology. 60 (2): 715–735. doi:10.1002/hep.27210. hdl:11577/3147929. PMID 25042402. S2CID 3155213.
Piccin A, Gulotta M, di Bella S, Martingano P, Crocè LS, Giuffrè M (February 2023). "Diverticular Disease and Rifaximin: An Evidence-Based Review". Antibiotics. 12 (3): 443. doi:10.3390/antibiotics12030443. PMC 10044695. PMID 36978310.
Bianchi M, Festa V, Moretti A, Ciaco A, Mangone M, Tornatore V, et al. (April 2011). "Meta-analysis: long-term therapy with rifaximin in the management of uncomplicated diverticular disease" (PDF). Alimentary Pharmacology & Therapeutics. 33 (8): 902–910. doi:10.1111/j.1365-2036.2011.04606.x. PMID 21366632.
Kruse E, Leifeld L (April 2015). "Prevention and Conservative Therapy of Diverticular Disease". Viszeralmedizin. 31 (2): 103–106. doi:10.1159/000377651. PMC 4789966. PMID 26989379.
Triantafyllou K, Sioulas AD, Giamarellos-Bourboulis EJ (2015). "Rifaximin: The Revolutionary Antibiotic Approach for Irritable Bowel Syndrome". Mini Reviews in Medicinal Chemistry. 16 (3): 186–192. doi:10.2174/1389557515666150722105340. PMID 26202193.
Weinstock LB, Steinhoff M (May 2013). "Rosacea and small intestinal bacterial overgrowth: prevalence and response to rifaximin". Journal of the American Academy of Dermatology. 68 (5): 875–876. doi:10.1016/j.jaad.2012.11.038. PMID 23602178.
Mahadevan U (August 2006). "Fertility and pregnancy in the patient with inflammatory bowel disease". Gut. 55 (8): 1198–1206. doi:10.1136/gut.2005.078097. PMC 1856272. PMID 16849349.
Robertson KD, Nagalli S (2022), "Rifaximin", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 32966000, retrieved 28 June 2022
Hoffman JT, Hartig C, Sonbol E, Lang M (May 2011). "Probable interaction between warfarin and rifaximin in a patient treated for small intestine bacterial overgrowth". The Annals of Pharmacotherapy. 45 (5): e25. doi:10.1345/aph.1P578. PMID 21505109. S2CID 12214785.
Brufani M, Cellai L, Marchi E, Segre A (December 1984). "The synthesis of 4-deoxypyrido[1',2'-1,2]imidazo[5,4-c]rifamycin SV derivatives". The Journal of Antibiotics. 37 (12): 1611–1622. doi:10.7164/antibiotics.37.1611. PMID 6526730.
Taylor DN (December 2005). "Poorly absorbed antibiotics for the treatment of traveler's diarrhea". Clinical Infectious Diseases. 41 (Supplement_8): S564 – S570. doi:10.1086/432953. PMID 16267720.
Pimentel M (January 2016). "Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea". Alimentary Pharmacology & Therapeutics. 43 (Suppl 1): 37–49. doi:10.1111/apt.13437. PMID 26618924.
Lee KJ (October 2015). "Pharmacologic Agents for Chronic Diarrhea". Intestinal Research. 13 (4): 306–312. doi:10.5217/ir.2015.13.4.306. PMC 4641856. PMID 26576135.
Braga D, Casali L, Grepioni F (August 2022). "The Relevance of Crystal Forms in the Pharmaceutical Field: Sword of Damocles or Innovation Tools?". International Journal of Molecular Sciences. 23 (16): 9013. doi:10.3390/ijms23169013. PMC 9408954. PMID 36012275.
Braga D, Casali L, Grepioni F (August 2022). "The Relevance of Crystal Forms in the Pharmaceutical Field: Sword of Damocles or Innovation Tools?". International Journal of Molecular Sciences. 23 (16): 9013. doi:10.3390/ijms23169013. PMC 9408954. PMID 36012275.
Noeske J, Nguenko PN (July 2002). "Impact of resistance to anti-tuberculosis drugs on treatment outcome using World Health Organization standard regimens". Transactions of the Royal Society of Tropical Medicine and Hygiene. 96 (4): 429–433. doi:10.1016/S0035-9203(02)90383-4. PMID 12497982.

ncbi.nlm.nih.gov

Koo HL, DuPont HL (January 2010). "Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases". Current Opinion in Gastroenterology. 26 (1): 17–25. doi:10.1097/MOG.0b013e328333dc8d. PMC 4737517. PMID 19881343.
Song KH, Jung HK, Kim HJ, Koo HS, Kwon YH, Shin HD, et al. (April 2018). "Clinical Practice Guidelines for Irritable Bowel Syndrome in Korea, 2017 Revised Edition". Journal of Neurogastroenterology and Motility. 24 (2): 197–215. doi:10.5056/jnm17145. PMC 5885719. PMID 29605976.
Iorio N, Malik Z, Schey R (2015). "Profile of rifaximin and its potential in the treatment of irritable bowel syndrome". Clinical and Experimental Gastroenterology. 8: 159–167. doi:10.2147/CEG.S67231. PMC 4467648. PMID 26089696.
Nelson RL, Suda KJ, Evans CT (March 2017). "Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults". The Cochrane Database of Systematic Reviews. 2017 (3) CD004610. doi:10.1002/14651858.CD004610.pub5. PMC 6464548. PMID 28257555.
Huang JS, Jiang ZD, Garey KW, Lasco T, Dupont HL (June 2013). "Use of rifamycin drugs and development of infection by rifamycin-resistant strains of Clostridium difficile". Antimicrobial Agents and Chemotherapy. 57 (6): 2690–2693. doi:10.1128/AAC.00548-13. PMC 3716149. PMID 23545528.
Kimer N, Krag A, Gluud LL (March 2014). "Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy". Patient Preference and Adherence. 8: 331–338. doi:10.2147/PPA.S41565. PMC 3964161. PMID 24672227.
Piccin A, Gulotta M, di Bella S, Martingano P, Crocè LS, Giuffrè M (February 2023). "Diverticular Disease and Rifaximin: An Evidence-Based Review". Antibiotics. 12 (3): 443. doi:10.3390/antibiotics12030443. PMC 10044695. PMID 36978310.
Kruse E, Leifeld L (April 2015). "Prevention and Conservative Therapy of Diverticular Disease". Viszeralmedizin. 31 (2): 103–106. doi:10.1159/000377651. PMC 4789966. PMID 26989379.
Mahadevan U (August 2006). "Fertility and pregnancy in the patient with inflammatory bowel disease". Gut. 55 (8): 1198–1206. doi:10.1136/gut.2005.078097. PMC 1856272. PMID 16849349.
Robertson KD, Nagalli S (2022), "Rifaximin", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 32966000, retrieved 28 June 2022
Lee KJ (October 2015). "Pharmacologic Agents for Chronic Diarrhea". Intestinal Research. 13 (4): 306–312. doi:10.5217/ir.2015.13.4.306. PMC 4641856. PMID 26576135.
Braga D, Casali L, Grepioni F (August 2022). "The Relevance of Crystal Forms in the Pharmaceutical Field: Sword of Damocles or Innovation Tools?". International Journal of Molecular Sciences. 23 (16): 9013. doi:10.3390/ijms23169013. PMC 9408954. PMID 36012275.
Braga D, Casali L, Grepioni F (August 2022). "The Relevance of Crystal Forms in the Pharmaceutical Field: Sword of Damocles or Innovation Tools?". International Journal of Molecular Sciences. 23 (16): 9013. doi:10.3390/ijms23169013. PMC 9408954. PMID 36012275.

dailymed.nlm.nih.gov

"Xifaxan- rifaximin tablet". DailyMed. 1 October 2019. Retrieved 11 November 2020.

rsc.org (Global: 2,020^th place; English: 1,872^nd place)

xlink.rsc.org

Braga D, Grepioni F, Chelazzi L, Campana M, Confortini D, Viscomi GC (2012). "The structure–property relationship of four crystal forms of rifaximin". CrystEngComm. 14 (20): 6404. Bibcode:2012CEG....14.6404B. doi:10.1039/c2ce25920f. ISSN 1466-8033.
Viscomi GC, Campana M, Barbanti M, Grepioni F, Polito M, Confortini D, et al. (2008). "Crystal forms of rifaximin and their effect on pharmaceutical properties". CrystEngComm. 10 (8): 1074. Bibcode:2008CEG....10.1074V. doi:10.1039/b717887e. ISSN 1466-8033.
Braga D, Grepioni F, Chelazzi L, Campana M, Confortini D, Viscomi GC (2012). "The structure–property relationship of four crystal forms of rifaximin". CrystEngComm. 14 (20): 6404. Bibcode:2012CEG....14.6404B. doi:10.1039/c2ce25920f. ISSN 1466-8033.

rusmedserv.com (Global: low place; English: low place)

"Alfa Normix". Russian medical server.

salix.com (Global: low place; English: low place)

"Investors | Salix Pharmaceuticals". Salix Pharmaceuticals.

semanticscholar.org (Global: 11^th place; English: 8^th place)

api.semanticscholar.org

Kane JS, Ford AC (2016). "Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome". Expert Review of Gastroenterology & Hepatology. 10 (4): 431–442. doi:10.1586/17474124.2016.1140571. PMID 26753693. S2CID 13607138.
Ponziani FR, Pecere S, Lopetuso L, Scaldaferri F, Cammarota G, Gasbarrini A (July 2016). "Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation". Expert Opinion on Drug Safety. 15 (7): 983–991. doi:10.1080/14740338.2016.1186639. PMID 27149541. S2CID 25426888.
Lawrence KR, Klee JA (August 2008). "Rifaximin for the treatment of hepatic encephalopathy". Pharmacotherapy. 28 (8): 1019–1032. doi:10.1592/phco.28.8.1019. PMID 18657018. S2CID 25662917. Free full text with registration at Medscape.
Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, et al. (August 2014). "Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver". Hepatology. 60 (2): 715–735. doi:10.1002/hep.27210. hdl:11577/3147929. PMID 25042402. S2CID 3155213.
Hoffman JT, Hartig C, Sonbol E, Lang M (May 2011). "Probable interaction between warfarin and rifaximin in a patient treated for small intestine bacterial overgrowth". The Annals of Pharmacotherapy. 45 (5): e25. doi:10.1345/aph.1P578. PMID 21505109. S2CID 12214785.

web.archive.org (Global: 1^st place; English: 1^st place)

"Drug Approval Package: Xifaxan (Nfaximin) NDA #021361". U.S. Food and Drug Administration (FDA). Archived from the original on 19 March 2015. Retrieved 28 December 2024.
"FDA approves two therapies to treat IBS-D" (Press release). U.S. Food and Drug Administration (FDA). Archived from the original on 26 January 2018. Retrieved 16 December 2019.

webmd.com (Global: 1,169^th place; English: 1,075^th place)

"Rifaximin Oral: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing". www.webmd.com. Retrieved 27 June 2022.

worldcat.org (Global: 5^th place; English: 5^th place)

search.worldcat.org

Braga D, Grepioni F, Chelazzi L, Campana M, Confortini D, Viscomi GC (2012). "The structure–property relationship of four crystal forms of rifaximin". CrystEngComm. 14 (20): 6404. Bibcode:2012CEG....14.6404B. doi:10.1039/c2ce25920f. ISSN 1466-8033.
Viscomi GC, Campana M, Barbanti M, Grepioni F, Polito M, Confortini D, et al. (2008). "Crystal forms of rifaximin and their effect on pharmaceutical properties". CrystEngComm. 10 (8): 1074. Bibcode:2008CEG....10.1074V. doi:10.1039/b717887e. ISSN 1466-8033.
Braga D, Grepioni F, Chelazzi L, Campana M, Confortini D, Viscomi GC (2012). "The structure–property relationship of four crystal forms of rifaximin". CrystEngComm. 14 (20): 6404. Bibcode:2012CEG....14.6404B. doi:10.1039/c2ce25920f. ISSN 1466-8033.

zydushealthcare.com (Global: low place; English: low place)

"Brands". Zydus Healthcare Limited. Retrieved 28 June 2022.

Rifaximin (English Wikipedia)

canada.ca (Global: 1,712th place; English: 1,063rd place)

canada.ca

health-products.canada.ca

doi.org (Global: 2nd place; English: 2nd place)

drugbank.ca (Global: 4,294th place; English: 6,357th place)

drugs.com (Global: 399th place; English: 333rd place)

europa.eu (Global: 68th place; English: 117th place)

ema.europa.eu

fda.gov (Global: 447th place; English: 338th place)

accessdata.fda.gov

fda.gov

fiercepharma.com (Global: low place; English: 8,921st place)

hal.science (Global: low place; English: low place)

handle.net (Global: 102nd place; English: 76th place)

hdl.handle.net

harvard.edu (Global: 18th place; English: 17th place)

ui.adsabs.harvard.edu

ipindia.gov.in (Global: low place; English: low place)

laboratoriosmicrosules.com (Global: low place; English: low place)

marketwatch.com (Global: 1,303rd place; English: 808th place)

medlineplus.gov (Global: 1,581st place; English: 1,299th place)

medscape.com (Global: 719th place; English: 636th place)

nih.gov (Global: 4th place; English: 4th place)

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

dailymed.nlm.nih.gov

rsc.org (Global: 2,020th place; English: 1,872nd place)

xlink.rsc.org

rusmedserv.com (Global: low place; English: low place)

salix.com (Global: low place; English: low place)

semanticscholar.org (Global: 11th place; English: 8th place)

api.semanticscholar.org

web.archive.org (Global: 1st place; English: 1st place)

webmd.com (Global: 1,169th place; English: 1,075th place)

worldcat.org (Global: 5th place; English: 5th place)

search.worldcat.org

zydushealthcare.com (Global: low place; English: low place)

canada.ca (Global: 1,712^th place; English: 1,063^rd place)

doi.org (Global: 2^nd place; English: 2^nd place)

drugbank.ca (Global: 4,294^th place; English: 6,357^th place)

drugs.com (Global: 399^th place; English: 333^rd place)

europa.eu (Global: 68^th place; English: 117^th place)

fda.gov (Global: 447^th place; English: 338^th place)

fiercepharma.com (Global: low place; English: 8,921^st place)

handle.net (Global: 102^nd place; English: 76^th place)

harvard.edu (Global: 18^th place; English: 17^th place)

marketwatch.com (Global: 1,303^rd place; English: 808^th place)

medlineplus.gov (Global: 1,581^st place; English: 1,299^th place)

medscape.com (Global: 719^th place; English: 636^th place)

nih.gov (Global: 4^th place; English: 4^th place)

rsc.org (Global: 2,020^th place; English: 1,872^nd place)

semanticscholar.org (Global: 11^th place; English: 8^th place)

web.archive.org (Global: 1^st place; English: 1^st place)

webmd.com (Global: 1,169^th place; English: 1,075^th place)

worldcat.org (Global: 5^th place; English: 5^th place)